IN2014CN02478A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02478A
IN2014CN02478A IN2478CHN2014A IN2014CN02478A IN 2014CN02478 A IN2014CN02478 A IN 2014CN02478A IN 2478CHN2014 A IN2478CHN2014 A IN 2478CHN2014A IN 2014CN02478 A IN2014CN02478 A IN 2014CN02478A
Authority
IN
India
Prior art keywords
lower alkyl
hydrogen
cycloalkyl
attached
form together
Prior art date
Application number
Other languages
English (en)
Inventor
Georg Jaeschke
Lothar Lindemann
Antonio Ricci
Daniel Rueher
Heinz Stadler
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014CN02478A publication Critical patent/IN2014CN02478A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2478CHN2014 2011-10-07 2012-10-04 IN2014CN02478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11184331 2011-10-07
PCT/EP2012/069599 WO2013050454A1 (en) 2011-10-07 2012-10-04 Ethynyl derivatives as mglur5 allosteric modulators

Publications (1)

Publication Number Publication Date
IN2014CN02478A true IN2014CN02478A (es) 2015-06-19

Family

ID=46968237

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2478CHN2014 IN2014CN02478A (es) 2011-10-07 2012-10-04

Country Status (26)

Country Link
US (1) US8969338B2 (es)
EP (1) EP2763977B1 (es)
JP (1) JP5840793B2 (es)
KR (1) KR101637792B1 (es)
CN (1) CN103857668B (es)
AR (1) AR088246A1 (es)
AU (1) AU2012320598B2 (es)
BR (1) BR112014007898A2 (es)
CA (1) CA2850082C (es)
CL (1) CL2014000819A1 (es)
CO (1) CO6900143A2 (es)
CR (1) CR20140094A (es)
EA (1) EA024973B1 (es)
EC (1) ECSP14013296A (es)
ES (1) ES2564884T3 (es)
HK (1) HK1195298A1 (es)
IL (1) IL231783A (es)
IN (1) IN2014CN02478A (es)
MX (1) MX360667B (es)
MY (1) MY170822A (es)
PE (1) PE20141556A1 (es)
SG (1) SG11201401322UA (es)
TW (1) TWI468401B (es)
UA (1) UA110862C2 (es)
WO (1) WO2013050454A1 (es)
ZA (1) ZA201402069B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
MY171517A (en) * 2012-10-18 2019-10-16 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
UA116023C2 (uk) * 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
AR097721A1 (es) * 2013-09-25 2016-04-13 Hoffmann La Roche Derivados de etinilo
JP6603334B2 (ja) 2015-06-03 2019-11-06 エフ.ホフマン−ラ ロシュ アーゲー エチニル誘導体
PE20180356A1 (es) 2015-07-15 2018-02-21 Hoffmann La Roche Derivados de etinilo como moduladores del receptor metabotropico del glutamato
CN106632243B (zh) * 2015-10-28 2019-03-15 华领医药技术(上海)有限公司 吡咯烷衍生物
RU2745068C2 (ru) 2016-07-18 2021-03-18 Ф. Хоффманн-Ля Рош Аг Производные этинила
CN111032659B (zh) * 2017-08-17 2022-09-09 豪夫迈·罗氏有限公司 用于治疗诸如帕金森病的疾病的咪唑并[1,2-a]咪唑-2-酮衍生物
US20240101549A1 (en) 2020-12-17 2024-03-28 Astrazeneca Ab N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3213780B2 (ja) 1993-12-21 2001-10-02 キヤノン株式会社 光学活性化合物、これを含有する液晶組成物、該液晶組成物を用いた液晶素子並びにこれらを用いた表示方法、表示装置
JPH09151179A (ja) 1995-11-30 1997-06-10 Canon Inc 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた液晶装置及び表示方法
US6410728B1 (en) 2000-08-31 2002-06-25 Abbott Laboratories Oxazolidinone chemotherapeutic agents
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
MX2009013169A (es) * 2007-06-03 2010-04-30 Univ Vanderbilt Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos.
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) * 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
CN103492374B (zh) * 2011-04-26 2016-06-01 霍夫曼-拉罗奇有限公司 吡唑烷-3-酮衍生物
AU2012247653B2 (en) * 2011-04-26 2016-05-26 F. Hoffmann-La Roche Ag Ethynyl derivatives as positive allosteric modulators of the mGluR5

Also Published As

Publication number Publication date
CO6900143A2 (es) 2014-03-20
KR101637792B1 (ko) 2016-07-07
KR20140077943A (ko) 2014-06-24
CN103857668A (zh) 2014-06-11
EA024973B1 (ru) 2016-11-30
CN103857668B (zh) 2016-04-13
CR20140094A (es) 2014-05-15
ZA201402069B (en) 2015-03-25
MX360667B (es) 2018-11-13
PE20141556A1 (es) 2014-10-30
US20130090332A1 (en) 2013-04-11
AR088246A1 (es) 2014-05-21
NZ621894A (en) 2016-03-31
MX2014004144A (es) 2014-07-28
WO2013050454A1 (en) 2013-04-11
TW201321365A (zh) 2013-06-01
IL231783A0 (en) 2014-05-28
US8969338B2 (en) 2015-03-03
IL231783A (en) 2015-09-24
CA2850082C (en) 2019-05-28
CA2850082A1 (en) 2013-04-11
TWI468401B (zh) 2015-01-11
SG11201401322UA (en) 2014-09-26
JP5840793B2 (ja) 2016-01-06
MY170822A (en) 2019-09-01
AU2012320598A1 (en) 2014-03-13
UA110862C2 (uk) 2016-02-25
AU2012320598B2 (en) 2016-10-13
CL2014000819A1 (es) 2014-09-22
ES2564884T3 (es) 2016-03-29
EP2763977B1 (en) 2016-02-24
ECSP14013296A (es) 2014-05-31
HK1195298A1 (zh) 2014-11-07
JP2014528435A (ja) 2014-10-27
EP2763977A1 (en) 2014-08-13
EA201490722A1 (ru) 2014-07-30
BR112014007898A2 (pt) 2017-04-04

Similar Documents

Publication Publication Date Title
IN2014CN02478A (es)
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
AR080878A1 (es) Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos.
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
MY162998A (en) Ethynyl derivatives
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
MX338631B (es) 5-(fenil/piridinil-etinil)-2-piridina/ 2-pirimidina-carboxamidas como moduladores del receptor de glutamato metabotropico del subtipo 5 (mglur5).
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
MY165141A (en) Pyrazolidin-3-one derivatives
PH12016500427A1 (en) Ethynyl derivatives
IN2014CN02477A (es)
PH12014502695A1 (en) Arylethynyl derivatives
PH12015500261A1 (en) Arylethynyl pyrimidines
PH12015500538B1 (en) Arylethynyl derivatives